结合性利尿疗法治疗心力衰竭:来自GUIDE-IT的见解
Jeffery Budweg1, Mustafa M Ahmed1, Juan R Vilaro1
1Department of Medicine, Division of Cardiology, University of Florida, Gainesville, FL, USA.
American heart journal plus : cardiology research and practice
|September 2, 2024
概括
结合性利尿疗法 (CDT) 在心力衰竭患者中没有增加全因死亡率,但与较早的住院住院有关. 需要进一步的研究才能充分了解CDT的风险和好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 利尿剂对于控制心力衰竭中的液体平衡至关重要.
- 循环利尿剂是标准的,但与 thiazides 结合利尿疗法 (CDT) 用于利尿耐药性.
研究的目的:
- 为了分析GUIDE-IT研究数据.
- 评估CDT对心力衰竭患者全因死亡率和初次住院时间的影响.
主要方法:
- 来自GUIDE-IT研究的894名患者的分析.
- 在单独循环利尿剂 (733名患者) 与CDT (161名患者) 中分层.
- 卡普兰-梅尔曲线和逻辑等级的p值被用于比较.
主要成果:
- 单独使用循环利尿剂和CDT组之间所有原因死亡率没有显著差异 (p=0.083).
- 亚组分析也显示没有显著的死亡率差异.
- 在CDT组中,首次住院的时间显著减少 (280.5天 vs 407.2天,p < 0.0001).
结论:
- CDT与更早的住院病例有关,但并没有增加全因死亡率.
- 需要进一步的前性研究来阐明CDT的完整的风险益处概况.
相关概念视频
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Antihypertensive Drugs: Potassium-Sparing Diuretics
476
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
476
Antihypertensive Drugs: Action of Diuretics
634
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
634


